Epidemiology of Colorectal Cancer in Average Risk Adults 20–39 Years of Age: A Population-Based National Study

Glover, Michael; Mansoor, Emad; Panhwar, Muhammad Siyab; Parasa, Sravanthi; Cooper, Gregory S.

doi:10.1007/s10620-019-05690-8

Cited by 68 publications

(99 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Explorys has the unique ability of defining index events and implementation of temporal relationships 17,18 . Using this temporal relationship, we excluded all patients with any diagnosis of IBD, CD, UC or indeterminate colitis prior to exposure to the interventions (weight loss surgery or medications), or at the time of enrolment in Explorys (for the obese control cohort).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications

Kochhar

Desai

Syed

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: An association between bariatric surgery and development of de-novo inflammatory bowel disease (IBD) has been observed.Aim: To evaluate further the association among bariatric surgery, weight loss medications, obesity and new-onset IBD. Methods: Using Explorys, a population-based Health Insurance Portability andAccountability Act compliant database, we estimated the prevalence of de-novo IBD among patients treated with bariatric surgery (Roux-en-Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding) (n = 60 870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide) (n = 193 790) compared with obese controls (n = 5 021 210), between 1999 and 2018.Results: The prevalence of de-novo IBD was lower among obese patients exposed to bariatric surgery (7.72 per 1000 patients) or weight loss medications (7.22 per 1000 patients) compared with patients with persistent obesity not exposed to these interventions (11.66 per 1000 patients, P < 0.0001). The risk reduction for de-novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de-novo IBD compared with the persistent obese control cohort. Conclusion:Obese patients undergoing treatment with bariatric surgery or weight loss medications are at a lower risk for developing de-novo IBD compared with persistently obese controls not exposed to these interventions. These data suggest that obesity and ineffective management of obesity are risk factors for de-novo IBD.Further research is needed to confirm these observations and understand potential mechanisms.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Bonferroni correction was used for statistically significant results (P = 0.05/10). Rates were reported standardised to 1000 persons and compared between groups using prevalence odds ratios (OR) with 95% Confidence Intervals (CI) 17,19,20 …”

Section: Methodsmentioning

confidence: 99%

Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications

Kochhar

Desai

Syed

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of 30 prospective studies by Larsson and Wolk reported that for every 5 kg/m 2 increase in BMI, the risk of colorectal cancer increased by 30% [11]. Among several factors, a very recent population based study carried out in the USA confirmed that obesity, diabetes mellitus, family history of other malignancy, and smoking independently increase the odds ratio for the occurrence of colorectal cancer [83]. Inflammatory cytokines appear to play a key role in linking obesity and colorectal carcinogenesis particularly so for IL-6 and tumor necrosis factor-α [84,85]; a recent study also describing IL-13 as a potential factor involved in the development of obesity-related colon cancer onset [86].…”

Section: Gi Cancermentioning

confidence: 99%

Role of Overweight and Obesity in Gastrointestinal Disease

et al. 2019

View full text Add to dashboard Cite

The prevalence of obesity is increasing worldwide, leading to a severe impairment of overall health. Actually, obesity has been associated with several pathological conditions, causing an excess overall mortality. In particular, overweight and obesity are well known risk factors for a variety of gastrointestinal (GI) disorders i.e., functional GI disorders as well as, inflammatory bowel disease (IBD), pancreatitis, and GI cancer. The aim of the present review is to summarize the potential role of overweight and obesity in GI disease with particular focus on plausible biological mechanisms that could explain the association between obesity and GI disease based on the most recent evidence in the literature.

show abstract

“…In 2015, there were 376,000 new cases and 191,000 deaths in China [459]. The overall incidence of CRC is decreasing in many high-income countries, although reported significant increase in Denmark, New Zealand, Australia, UK and Canada, mainly driven by increases in distal (left) tumors of the colon and predominant in [460][461][462][463][464][465][466][467]. Lifestyle determines around 50% to 60% incident of CRC irrespective of age [468][469][470][471].…”

Section: D) Colorectal Cancermentioning

confidence: 99%

Clinical Pharmacists in Chronic Care

Mohiuddin¹

2019

GJMR

View full text Add to dashboard Cite

Pharmacy practice has changed significantly lately. The professionals have the chance to contribute straightforwardly to patient consideration so as to lessen morbimortality identified with medication use, promoting wellbeing and preventing diseases. Healthcare organizations worldwide are under substantial pressure from increasing patient demand. Unfortunately, a cure is not always possible particularly in this era of chronic complications, and the role of physicians has become limited to controlling and palliating symptoms.The increasing population of patients with longterm conditions are associated with high levels of morbidity, healthcare costs and GP workloads. Clinical pharmacy took over an aspect of medical care that had been partially abandoned by physicians. Overburdened by patient loads and the explosion of new drugs, physicians turned to pharmacists more and more for drug information, especially within institutional settings. Once relegated to counting and pouring, pharmacists headed institutional reviews of drug utilization and served as consultants to all types of health-care facilities. In addition, when clinical pharmacists are active members of the care team, they enhance proficiency by: Providing critical input on medicine use and dosing. Working with patients to solve problems with their medications and improve compliance.

show abstract

Epidemiology of Colorectal Cancer in Average Risk Adults 20–39 Years of Age: A Population-Based National Study

Cited by 68 publications

References 24 publications

Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications

Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications

Role of Overweight and Obesity in Gastrointestinal Disease

Clinical Pharmacists in Chronic Care

Contact Info

Product

Resources

About